Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

CB2 Acquires New Jersey Medical Cannabis Group

Stockhouse Editorial
0 Comments| June 26, 2019

{{labelSign}}  Favorites
{{errorMessage}}

/stockhouse.com/companies/quote?symbol=c.cbii" style="box-sizing: inherit; outline: 0px">CSE:CBII,Forum) stated this week that it will take over patient care for one of New Jersey’s largest medical cannabis evaluation and education clinic groups, New Jersey Alternative Medicine, on July 1st, 2019.

For more on this latest acquisition, click here.

A provider of predictive analytics tools, data-driven software and comprehensive services across the cannabis value chain, CB2 recently announced its next shareholder meetingscheduled for June 27th, 2019 at 10am EST at its head office at 5045 Orbitor Drive, Mississauga, ON.


FULL DISCLOSURE: CB2 Insights Inc. is a client of Stockhouse Publishing.




{{labelSign}}  Favorites
{{errorMessage}}

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company